ArticleEClinicalMedicine2024
Projecting the economic burden of chronic kidney disease at the patient level (
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review.Current diabetes reviews · 2026Pooled it
- When Tech Meets Touch: Multistakeholder Perspectives and Implementation Strategies for eHealth in Chronic Kidney Disease: A Systematic Review Using Computational Linguistics.Journal of nursing management · 2026Pooled it
- Global prevalence of chronic kidney disease and its influencing factors among chronic hepatitis B: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Enhanced external counter pulsation as a novel therapy to maintain cardiac output during hemodialysis: a preliminary randomized controlled study.Scientific reports · 2025Trial
- Efficacy of a mobile health application on self-management among Japanese patients with chronic kidney disease.Clinical and experimental nephrology · 2025Trial
- Beyond urinalysis: a review of life-course chronic kidney disease screening across health examination systems in Japan.Clinical and experimental nephrology · 2026Review
- Cost-effectiveness of multidisciplinary care for patients with chronic kidney disease in Japan.Clinical and experimental nephrology · 2026Article
- Vaccination of Patients with Chronic Kidney Disease and Cocooning Strategy in a Tertiary Hospital.Vaccines · 2026Article
- Perceived Impacts and Concerns in the Daily Life of People with Chronic Kidney Disease: A Qualitative Study.Portuguese journal of public health · 2026Article
- Urinary Extracellular Vesicles Biomarkers in CKD: Clinical Laboratory Translation.Diagnostics (Basel, Switzerland) · 2026Review
- Atmospheric stressors and kidney diseases.Nature reviews. Nephrology · 2026Review
- Chronic kidney disease-associated cardiomyopathy: clinical features, pathophysiology and treatment.Nature reviews. Cardiology · 2026Review
- Beyond Diffusion: Harnessing Physical Principles for Precision KRT.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings.Kidney medicine · 2026Article
- Temporal trends in healthcare resource use and costs of chronic kidney disease in a Spanish population: the REDIC study.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia.International journal of molecular sciences · 2026Review
- Reimagining kidney value-based care: leveraging data science for dynamic, clinician-level risk prediction.Current opinion in nephrology and hypertension · 2026Review
- Deep Learning Enables Automated Segmentation and Quantification of Ultrastructure from Transmission Electron Microscopy Images.bioRxiv : the preprint server for biology · 2026Article
- Experience and Outcomes of a Dedicated Cardio-Nephrology Service: A Step toward Integrated Cardiovascular-Kidney-Metabolic Syndrome Care.Kidney360 · 2026Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing burden of chronic kidney disease (CKD) places substantial financial pressures on patients, healthcare systems, and society. An understanding of the costs attributed to CKD and kidney replacement therapy (KRT) is essential for evidence-based policy making. Methods: A microsimulation model was developed that generated virtual populations using national demographics, relevant literature, and renal registries for the 31 countries/regions included. Patient-level country/region-specific cost data were extracted via a pragmatic local literature review and under advisement from local experts. Direct cost projections were generated for diagnosed CKD (by age, stage 3a-5), KRT (by modality), cardiovascular complications (heart failure, myocardial infarction, stroke), and comorbidities (hypertension, type 2 diabetes). Findings: For the 31 countries/regions, Interpretation: The economic burden of CKD is projected to increase from 2022 to 2027. KRT contributes disproportionately to this burden. Earlier diagnosis and proactive management could slow disease progression, potentially alleviating the substantial costs associated with later CKD stages. Data presented here can be used to inform healthcare resource allocation and shape future policy. Funding: AstraZeneca.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.